Bleeding patterns in recent postmenopausal outpatients with uterine myomas: comparison between two regimens of HRT.
OBJECTIVE
To evaluate and to compare the bleeding patterns obtained with two regimens of hormone replacement therapy given to early postmenopausal women with asymptomatic uterine leiomyomas.


METHODS
In this randomised prospective 1-year study 50 early postmenopausal women with one to four asymptomatic uterine leiomyomas were enrolled into two study-groups to take two regimens of hormone replacement therapy for 12 28-day cycles: (A) Tibolone, 2.5 mg/day; (B) conjugated equine estrogens (CEE), 0.625 mg/day plus medroxyprogesterone acetate (MPA), 5 mg/day. The bleeding patterns and the changes in uterine volume of the 47 outpatients who completed the study were evaluated and compared.


RESULTS
Amenorrhea incidence was higher in group A (75.0% of the cycles) than in group B (65.6% of the cycles), while irregular bleeding and irregular spotting incidences were higher in group B (29.7 and 4.7% of the cycles, respectively) compared to group A (22.6 and 2.4% of the cycles, respectively). The mean bleeding and spotting lengths were not statistically different between patients in group A and those in group B. Finally, at the end of the study period transvaginal ultrasonography showed no significant change in leiomyoma size.


CONCLUSIONS
The results demonstrate that, in early postmenopausal patients with asymptomatic uterine leiomyomas, Tibolone treatment seems to be preferable compared to CEE-MPA continuous combined treatment in relation to the lesser occurrence of irregular bleeding. Furthermore, neither Tibolone nor CEE-MPA therapy, at the doses used here, promote fibroid growth.
Department of Obstetrics and Gynaecology, University of Bologna, Italy.
D
D
de Aloysio
P
P
Altieri
P
P
Penacchioni
M
M
Salgarello
V
V
Ventura
D045930:Anabolic Agents / Q000008:administration & dosage*; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage*; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D007889:Leiomyoma / Q000503:physiopathology*; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D008593:Menopause / Q000187:drug effects* / Q000502:physiology; D008597:Menstrual Cycle / Q000187:drug effects* / Q000502:physiology; D008875:Middle Aged; D009652:Norpregnenes / Q000008:administration & dosage*; D011446:Prospective Studies; D014594:Uterine Neoplasms / Q000503:physiopathology*
D045930:Anabolic Agents; D004966:Estrogens, Conjugated (USP); D009652:Norpregnenes; D017258:Medroxyprogesterone Acetate; C027385:tibolone